Published • loading... • Updated
Transgene jumps 20% on positive cancer vaccine data in early trial
4 Articles
4 Articles
No relapses in three years. This result obtained in the treatment of ENT cancer is very promising. It has just been published in the international journal Nature Communications and involves Toulouse teams of...
Transgene jumps 20% on positive cancer vaccine data in early trial
Sept 3 (Reuters) - Transgene shares surged 20% in early Paris trading on Thursday, after the French biotechnology company reported positive Phase 1 trial data on its vaccine candidate for head and neck cancer. Investors have rewarded encouraging data...
Positive results from phase I trials for the cancer vaccine.
Coverage Details
Total News Sources4
Leaning Left1Leaning Right0Center1Last UpdatedBias Distribution50% Left, 50% Center
Bias Distribution
- 50% of the sources lean Left, 50% of the sources are Center
50% Center
L 50%
C 50%
Factuality
To view factuality data please Upgrade to Premium
